ClinicalTrials.gg
RecruitingNCT07951489Updated Nov 20, 2026

At Home Use of Noninvasive Vagus Nerve Stimulation Following TBI to Improve Cognition.

An interventional study of Transcutaneous Vagus Nerve Stimulation (tVNS) and Tancutaneous Vagus Nerve Stimulation (Sham then Active) in TBI Traumatic Brain Injury, sponsored by Shirley Ryan AbilityLab. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Brain Injuries, Traumatic by Shirley Ryan AbilityLab — 3 open to participants now, 3 under way, none of them phase 3. Brain Injuries, Traumatic · Shirley Ryan AbilityLab.

Started
2026
with 2 others
No phase
8 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Brain Injuries, Traumatic by Shirley Ryan AbilityLab, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 10th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

3 of the 10 studies in Brain Injuries, Traumatic by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Brain Injuries, Traumatic by Shirley Ryan AbilityLab, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether individuals with TBI can comfortably and consistently use transcutaneous vagus nerve stimulation (tVNS) at home and to identify barriers that may affect participation. A secondary objective is to obtain preliminary data to examine whether at-home tVNS is associated with improvement in cognitive skills as well as any improvement in patient reported outcomes such as sleep, mood, or fatigue.

Read the detailed description

This is a sham controlled pilot study to evaluate the feasibility and preliminary efficacy of remotely supervised, at-home delivery of tVNS in individuals with TBI during the post-acute recovery phase. Eligible participants will complete a 4-week tVNS intervention protocol at home. Mixed methods (quantitative and qualitative) will be used to evaluate outcomes. Eligible participants will be invited to initial baseline assessment and tVNS training session (Visit 1). Then, they will be randomly allocated to recieve either active or sham stimulation for the first two weeks of at-home administration period. They will then return for a min-intervention assessment (Visit 2). After the mid-intervention assessment, they will return home and recieve active stimulation for the remaining two weeks. Lastly, they will return to a post- intervention assessment (Visit 3). In the assessment sessions participants will complete tasks of set shifting and working memory, core executive functions, as well as complete surveys regarding fatigue, sleep, and overall quality of life.

03

Conditions studied

  • TBI Traumatic Brain Injury

Keywords

  • Traumatic Brain Injury
  • Executive Functions
  • Transcuaneous Vagus Nerve Stimulation (tVNS)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years Formally diagnosed with traumatic brain injury.
  • Ability to independently use a keyboard.
  • Ability to independently apply the electrode and adjust stimulation or have a designated caregiver available to be trained and assist with these tasks.
  • Able to understand and communicate in English (according to clinical judgment).
  • Able to independently provide consent to participate. -Able to come in person to Shirley Ryan AbilityLab in Chicago, IL for three visits over 5 weeks.

Exclusion criteria

Exclusion Criteria:

  • Acute medical issues requiring close physician or nursing monitoring. Bioelectrical implants, cerebral shunts, including pacemakers.
  • Anyone with sore or diseased skin area in the ear
  • Pregnancy or persons who are lactating.
  • Cardiac arrhythmia.
  • Epilepsy or seizure disorders.
  • Significant gross or fine motor weakness.
  • Significant, ongoing communication or comprehension impairments (such as aphasia) that would affect an individual's ability to complete the required assessments.
  • Severely impaired memory retention
  • Current major depression diagnosis.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Active Stimulation

    Initial baseline assessment completed Day 0. Active stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device , for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, another two weeks (Day 16-29) of active stimulation at home followed by a post intervention assessment session.

    Device: Transcutaneous Vagus Nerve Stimulation (tVNS)

  • Sham comparator
    Sham Stimulation

    Initial baseline assessment completed Day 0. Sham stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device, for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, participant will switch to recieve active stimulation for the remaining 2 week at home (Day 16-29) followed by a post intervention assessment session.

    Device: Tancutaneous Vagus Nerve Stimulation (Sham then Active)

Interventions

  • DeviceTranscutaneous Vagus Nerve Stimulation (tVNS)

    tVNS stimulation at home for atleast one hour a day for 4 weeks.

  • DeviceTancutaneous Vagus Nerve Stimulation (Sham then Active)

    Participants will recieve two weeks of sham stimulation for atleast one hour a day, followed by 2 weeks of active stimulation for atleast one hour a day.

06

What researchers measure

Primary outcomes

  1. Recording the number of participant who completed at least 75% of the sessions out of the number of participants enrolled in the study.

    Time frame: Post Intervention Assessment Day 30

  2. Semi-structured interviews will collect feedback on perceived benefit, usability, logistical challenges, and barriers to adherence.

    Time frame: Post Intervention Assessment Session Day 30

Secondary outcomes

  1. N-Back

    In the N-Back Task, participants are presented a series of visual stimuli. They are asking for each stimulus whether is matches a stimulus n-trials before. For example, in a 2-back task, in which the trials consist of letters, participants have to decide whether the current letter is the same as the letter in the trial n-2. We will use a computerized version of this task.

    Time frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

  2. California Verbal Learning Test

    The California Verbal Learning Test evaluates the ability to encode, recall, and recognize verbally presented information across multiple learning trials and delayed recall conditions. Participants are read multiple lists of words and asked to recall specific words at different time allotments.

    Time frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

  3. Trail Making A&B

    Trail Making Part A requires participant to draw a line between circles containing numbers in ascending order. Part B requires participants to alternate drawing a line between ascending letters and numbers. The key measures are the time required to complete and the number of errors made in Part A and Part B. The test measures various aspects of cognition including attention, visual search, motor coordination, reasoning, and task switching.

    Time frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

  4. Conners Continuous Performance Test 3rd Edition

    CPT-3 is a computerized task requires of pressing the space bar on a computer keyboard after any letter is presented on the screen, except for the letter "X". This test lasts about 14 minutes. It measures several aspects of sustained attention, including inattention, impulsivity, and vigilance captured by measuring response styles, errors, and response times.

    Time frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 24 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951489
Collaborators
Kiwanis Neurological Research Foundation
Responsible party
Elliot Roth (Attending Physician, Shirley Ryan AbilityLab) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Kathryn Magee, MHS., CCC-SLP/L, CBIS
Contact
tvns_research@sralab.org
312 238 6451
Shira Cohen-Zimerman, PhD
Contact
tvns_research@sralab.org
312 238 6450

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion